To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

What Was Tested

The trial (phase 1) is built around Retatrutide.

It had 1 arm (groups): Retatrutide (experimental).

The registry classes the interventions as drug.

Who Took Part

The registry lists 30 actual participants took part.

It was open to people of any sex aged from 21 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and vital signs. Have a body mass index (BMI) within the range 22.0 to 35.0 kilogram per square meter (kg/m2) (inclusive) at screening.

The full record lists 2 inclusion and 4 exclusion criteria; among the exclusions: had any of the following cardiovascular conditions prior to screening: acute myocardial infarction, cerebrovascular accident, unstable angina, or hospitalization due to congestive heart failure.

How the Study Was Run

Design: sequential and open-label.

Being open-label, the Retatrutide study did not mask who received what.

It started in 2025-02-03 with completion listed for 2025-04-15.

It ran at 1 site in Singapore.

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): PK: Maximum Concentration (Cmax) of Metoprolol (time frame: Day 1 to Day 3). PK: Cmax of Metoprolol with Retatrutide (time frame: Day 9 to Day 11).

It also tracked 1 secondary outcome, for example Number of Participants with an Incidence of Treatment Emergent Adverse Events TEAEs (TEAEs).

What This Means in Plain Language

Put simply, this is a phase 1 trial of Retatrutide in 30 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Retatrutide compound page, all human trials.